Is Colchicine the 2020 Comeback Kid?

Is Colchicine the 2020 Comeback Kid?

Colchicine has been used in medicine for > 2000 years and current established uses include treatment of gout, Familial Mediterranean Fever, and pericarditis, although it has been studied in a wide range of conditions including atrial fibrillation, cancer, and more recently prevention of ischemic events in patients with coronary heart disease. Despite lifestyle changes and significant advances in medicine and interventional cardiology, patients with coronary heart disease remain at high risk for cardiovascular events creating a continued focus on measures to mitigate risk. Will colchicine comeback to fame and help mitigate cardiovascular adverse events?

Upon successful completion of this application-based course, pharmacists and students should be able to:
1. Explain the mechanism of action for colchicine
2. Discuss the potential role of colchicine in coronary heart disease
3. Discuss the results and conclusions of the LoDoCo2 Trial
4. Review the clinical appropriateness of colchicine for the prevention of cardiovascular events in patients with established coronary heart disease

Lindsay Davis, PharmD, BCPS, ASH-CHC, TTS, FAzPA
Associate Professor
Midwestern University College of Pharmacy – Glendale

Lindsay Davis does not report any actual or potential conflicts of interest in relation to this continuing pharmacy education course. 

CEimpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. To obtain 1 contact hour of continuing pharmacy education credit (0.1 CEU), participants must read:

Nidorf SM, Fiolet ATL, Mosterd A, et al; LoDoCo2 Trial Investigators. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020 Aug 31. doi: 10.1056/NEJMoa2021372. Epub ahead of print. PMID: 32865380. Available here:  

The article this month is from The New England Journal of Medicine and may be behind a paywall. We encourage preceptors to take advantage of journal access through university affiliation. Additionally, a free account to provides access to 2 subscriber-only articles per month, if access through a university is not possible. 

*CEimpact provides you with two (2) opportunities to complete the exam. If there are two failed attempts, the participant will not receive CPE credit.

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Initial Release Date: December 9, 2020
Planned Expiration Date: December 9, 2023

Universal Activity Number (UAN): 0107-0000-20-349-H01-P
Application-based CPE Activity

CEImpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Obtain CPE credit by completing the course, followed by the exam and evaluation (if applicable). Once successfully completed, your course will appear in your Completed Courses tab. Access your CPE statement of credit at

¹CEImpact provides you with two (2) opportunities to complete the exam. The learner will not receive CPE credit after two failed attempts.

Additional information


1h 0m

Topic Designator

Disease State/Drug Therapy



ACPE Topic

01 Drug Therapy





Release Date






ACPE Number


This course is in our subscription.